United States Últimas notícias

Celsius Holdings (NASDAQ:CELH) reported a transformative first quarter for 2026, with record-breaking revenue and significant market share gains across the U.S. energy drink category.

Claritev (NYSE:CTEV) reported modest top-line growth for the first quarter of 2026, as the company continues to scale its data and insights platform aimed at healthcare affordability.

Lincoln National (NYSE:LNC) reported improved underlying financial performance for the first quarter of 2026, as core earnings growth across its primary business lines helped narrow its GAAP net loss.

Genesis Energy (NYSE:GEL) delivered a notable financial turnaround in the first quarter of 2026, transitioning back to profitability as its diversified midstream and industrial assets generated improved cash flows.

EPAM Systems (NYSE:EPAM) reported a solid start to 2026, with financial results that reflect steady demand for its specialized AI and digital transformation services.

Walker & Dunlop (NYSE:WD) reported an explosive start to 2026, characterized by a dramatic recovery in deal flow and a significant expansion of its servicing portfolio.

Primo Brands (NYSE:PRMB) reported a mixed start to 2026, with top-line growth exceeding internal expectations even as persistent cost pressures weighed on operational margins.

MDA Space (NYSE:MDA) delivered a robust start to 2026, reporting a uniform 32% year-over-year increase across its primary financial performance indicators.

Six Flags Entertainment (NYSE:FUN), North America’s largest regional amusement park operator, reported a strong start to the 2026 season with record first-quarter revenue and significant gains in guest monetization.

ProFrac Holding (NASDAQ:ACDC) reported a sequential uptick in revenue for the first quarter of 2026, though the company continues to face margin pressure amid shifting dynamics in the North American pressure pumping market.

Canadian Natural Resources (NYSE:CNQ) delivered a strong first-quarter 2026 performance, marked by high operational reliability and significant capital returns to shareholders.

Oculis Holding (NASDAQ:OCS) has received a Special Protocol Assessment (SPA) from the U.S. Food and Drug Administration (FDA) for its Phase 3 PIONEER-1 trial.